PMGC HOLDINGS INC. Increase (Decrease) in Accounts Receivable
PMGC HOLDINGS INC. (ELAB) reported Increase (Decrease) in Accounts Receivable of $23.22 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2024-03-29
- PMGC HOLDINGS INC. increase (decrease) in accounts receivable for the quarter ending 2023-12-31 was $4.53M.
- PMGC HOLDINGS INC. increase (decrease) in accounts receivable for the quarter ending 2022-12-31 was -$13.80M.
- PMGC HOLDINGS INC. increase (decrease) in accounts receivable for fiscal 2023 was $23.22K, a 101.07% increase from fiscal 2022.
- PMGC HOLDINGS INC. increase (decrease) in accounts receivable for fiscal 2022 was $11.55K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|
| 2023-12-31 | $4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $23.22K 10-K · filed 2024-03-29 | |
| 2023-09-30 | -$4.51M 10-Q · filed 2023-12-11 | ||
| 2022-12-31 | -$13.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $11.55K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $13.81M 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |